Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G. Willett, Yves Boucher, Emmanuelle di Tomaso et al.|Nature Medicine|2004Cited by 2k
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersAparna R. Parikh, Ryan B. Corcoran, Ignaty Leshchiner et al.|Nature Medicine|2019Cited by 521
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyChristopher G. Willett, Dan G. Duda, Emmanuelle di Tomaso et al.|Journal of Clinical Oncology|2009Cited by 507
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419
Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsDirk Strumberg, Brian Schwartz, Jeffrey W. Clark et al.|The Oncologist|2007Cited by 418